Ceresoli GL, Aerts JG, Dziadziuszko R, et al. - Through STELLAR, a prospective, single-arm, phase 2 trial performed at 12 European academic and non-academic sites for treatment-naive individuals with histologically verified unresectable malignant pleural mesothelioma, researchers examined the activity of Tumour Treating Fields (TTFields) delivered to the thorax in combination with systemic chemotherapy for the front-line treatment of 80 individuals with unresectable malignant pleural mesothelioma. Anemia, neutropenia, and thrombocytopenia were the most prevalent grade 3 or worse adverse events. The only adverse event related to TTFields was skin reaction and it was reported as grade 1–2 in 53 individuals and as grade 3 in four. No treatment-related deaths were noted. Hence, this trial revealed promising overall survival outcomes, with no rise in systemic toxicity. Moreover, for the front-line treatment of unresectable malignant pleural mesothelioma, TTFields (150 kHz) transferred to the thorax concomitant with pemetrexed and platinum was an effective and secure combination.